Mirvie Inc
820 Dubuque Avenue
South San Francisco
CA
94080
United States
Website: https://mirvie.com/
Email: careers@mirvie.com
About Mirvie Inc
Mirvie is shaping the future of pregnancy health by predicting unexpected complications before they happen for the well-being of millions of moms and babies. Complications such as preterm birth, preeclampsia and gestational diabetes, affect 1 in 5 pregnancies, with large economic costs and lifelong health consequences for mom and baby. Our ground-breaking RNA platform is first to predict unexpected complications months before symptoms appear by revealing the underlying biology of each pregnancy. This breakthrough opens a new window into pregnancy health, allowing women to act and their doctors to intervene before unexpected complications become a crisis. Detection of early disease, at the individual level, also promises more equitable care than the use of broad sociodemographic factors that often result in bias. The idea for Mirvie was sparked by the personal experience of one of the founders whose daughter was born prematurely. Our team of world-class scientists and entrepreneurs has brought to market category-first, noninvasive tests used by millions. As a women’s health organization, Mirvie’s team shares a common purpose: to create a world where every pregnancy is as healthy as possible for both mom and baby. The company is headquartered in South San Francisco, California.
5 articles with Mirvie Inc
-
Mirvie Expands Leadership Team with Appointment of Alison Cowan, M.D. as Head of Medical Affairs
8/30/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, announced the appointment of Alison Cowan, M.D., M.S.C.R. as Head of Medical Affairs.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Health
5/17/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised a total of $90 million to date following the close of its Series B funding.
-
Late-breaking Data Presented at SMFM 2022 Annual Meeting Shows The Mirvie RNA Platform is First to Reveal The Underlying Biology of Preterm Birth
2/4/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, announced data presented at the Society for Maternal-Fetal Medicine 42nd Annual Pregnancy Meeting demonstrates the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.
-
Study Published in Nature Shows Mirvie Can Predict Pregnancy Complications Months Before They Happen Using New, Proprietary RNA Platform
1/5/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy.